# Experimental and In Silico Studies to Unravel the Antioxidant and Antibacterial Properties of Lichen Metabolites from Pseudocyphellaria compar and Pseudocyphellaria nudata

**Authors:** Mauricio A. Cuellar, Jessica Mejía, Helena Quintero-Pertuz, Alejandro Castro-Álvarez, Marco Mellado, Waleska Vera-Quezada, Gloria Montenegro, Christian Espinosa-Bustos, Raquel Bridi, Cristian O. Salas

PMC · DOI: 10.3390/antiox15010034 · Antioxidants · 2025-12-25

## TL;DR

This study explores lichen compounds that show strong antioxidant and antibacterial effects, particularly against S. pyogenes, and identifies a potential drug target.

## Contribution

The study combines experimental and computational methods to identify a potent lichen metabolite with promising antibacterial and antioxidant properties.

## Key findings

- Metabolite IX (physciosporin) showed the highest antioxidant activity linked to radical stability.
- Metabolite IX had an MIC of 0.97 μg/mL against S. pyogenes, outperforming streptomycin.
- RecA protein was identified as a potential antibacterial target with predicted binding sites.

## Abstract

Lichens are a source of diverse compounds with a wide range of biological activities, making them of significant interest for novel drug development. In this study, metabolites were extracted from Lobariaceae lichens, and their antioxidant and antibacterial properties were experimentally investigated and explained using various computational approaches. Specifically, four lichen metabolites were analyzed using three methods to assess their antioxidant capacity. Antibacterial activity assays were conducted against four pathogens, and the minimum inhibitory concentrations (MICs) of the most promising compounds were determined. Ab initio studies were performed to evaluate radical stability. A pharmacological target responsible for the antibacterial effect was identified, and possible binding sites and modes were studied in silico. Metabolite IX, physciosporin, exhibited the highest antioxidant activity, which was associated with the theoretical stability of the radical. Additionally, IX exhibited an MIC of 0.97 μg/mL against S. pyogenes, surpassing the potency of streptomycin. The RecA protein was identified as a potential target, and a possible binding site and pattern of interactions at that site were described. Finally, IX showed low cytotoxicity in human cancer cell lines and was predicted to have favorable oral absorption properties, supporting its potential as a promising antioxidant and antibacterial agent against S. pyogenes.

## Linked entities

- **Proteins:** RAD51 (RAD51 recombinase)
- **Chemicals:** physciosporin (PubChem CID 71439318), streptomycin (PubChem CID 5297)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), cytotoxicity (MESH:D064420)
- **Chemicals:** streptomycin (MESH:D013307), physciosporin (MESH:C000607989)
- **Species:** Homo sapiens (human, species) [taxon 9606], Streptococcus pyogenes (species) [taxon 1314]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12837165/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12837165/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12837165/full.md

---
Source: https://tomesphere.com/paper/PMC12837165